Literature DB >> 26444149

A comparison of single dose dexmedetomidine with propofol for the prevention of emergence delirium after desflurane anaesthesia in children.

J K Makkar1, N Bhatia1, I Bala1, D Dwivedi1, P M Singh1.   

Abstract

Emergence delirium is a common problem in children recovering from general anaesthesia. We performed a study comparing emergence characteristics in 100 patients who were randomly allocated to receive either 0.3 μg.kg(-1) dexmedetomidine, 1 mg.kg(-1) propofol or saline 0.9% and undergoing infra-umbilical surgery. The Pediatric Anesthesia Emergence Delirium scale was used to grade emergence delirium. Emergence delirium occurred in 9.4% of children in the dexmedetomidine group compared with 13.9% in the propofol group and 40.6% in the control group (p = 0.004). In the dexmedetomidine group, sedation occurred in 62.5% of children at 10 min after transfer to the recovery area, compared with 44.4% in the propofol group and 12.5% in the control group (p = 0.010). We conclude that dexmedetomidine significantly reduced the incidence of emergence delirium but this was at the expense of a greater incidence of sedation in the recovery period.
© 2015 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26444149     DOI: 10.1111/anae.13230

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

Review 1.  Pediatric Delirium: Evaluation, Management, and Special Considerations.

Authors:  Nasuh Malas; Khyati Brahmbhatt; Cristin McDermott; Allanceson Smith; Roberto Ortiz-Aguayo; Susan Turkel
Journal:  Curr Psychiatry Rep       Date:  2017-08-12       Impact factor: 5.285

2.  Prevention and Therapy of Pediatric Emergence Delirium: A National Survey.

Authors:  Christopher Huett; Torsten Baehner; Felix Erdfelder; Claudia Hoehne; Christian Bode; Andreas Hoeft; Richard K Ellerkmann
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

3.  Efficacy of 0.5 mg/kg of propofol at the end of anesthesia to reduce the incidence of emergence agitation in children undergoing general anesthesia with sevoflurane.

Authors:  Andi Ade Wijaya Ramlan; Dimas K Bonardo Pardede; Arif H M S Marsaban; Jefferson Hidayat; Fildza Sasri Peddyandhari
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2020-06-15

4.  Effect of different administration and dosage of dexmedetomidine in the reduction of emergence agitation in children: a meta-analysis of randomized controlled trials with sequential trial analysis.

Authors:  Xu Zhang; Yan Bai; Min Shi; Shaopeng Ming; Xiaogao Jin; Yubo Xie
Journal:  Transl Pediatr       Date:  2021-04

5.  Dexmedetomidine Acts via the JAK2/STAT3 Pathway to Attenuate Isoflurane-Induced Neurocognitive Deficits in Senile Mice.

Authors:  Yanna Si; Yuan Zhang; Liu Han; Lihai Chen; Yajie Xu; Fan Sun; Muhuo Ji; Jianjun Yang; Hongguang Bao
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

6.  Effect of Dexmedetomidine in children undergoing general anaesthesia with sevoflurane: a meta-analysis and systematic review.

Authors:  Wen Tang; DongWei He; YuLin Liu
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

7.  Optimal Dexmedetomidine Dose to Prevent Emergence Agitation Under Sevoflurane and Remifentanil Anesthesia During Pediatric Tonsillectomy and Adenoidectomy.

Authors:  Yan-Zhuo Zhang; Xue Wang; Jia-Min Wu; Chun-Yu Song; Xiao-Guang Cui
Journal:  Front Pharmacol       Date:  2019-09-19       Impact factor: 5.810

8.  Monochromic light reduces emergence delirium in children undergoing adenotonsillectomy; a double-blind randomized observational study.

Authors:  Adam C Adler; Brian H Nathanson; Arvind Chandrakantan
Journal:  BMC Anesthesiol       Date:  2021-09-08       Impact factor: 2.217

9.  Efficacy of different doses of dexmedetomidine as a rapid bolus for children: a double-blind, prospective, randomized study.

Authors:  Fang Chen; Chengyu Wang; Yi Lu; Mengmeng Huang; Zhijian Fu
Journal:  BMC Anesthesiol       Date:  2018-08-07       Impact factor: 2.217

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.